Search

Your search keyword '"Remy-Jardin M"' showing total 476 results
Start Over Author "Remy-Jardin M"
476 results on '"Remy-Jardin M"'

1. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version intégrale

Author

Cottin, V., Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clément, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C.-H., Montani, D., Prévot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P.-Y., Campana, M., Chalabreysse, L., Chatté, G., Debieuvre, D., Ferretti, G., Fourrier, J.-M., Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J.-P., Mehdaoui, A., Naccache, J.-M., Paganon, C., Rémy-Jardin, M., Si-Mohamed, S., and Terrioux, P.

Published
2022
Full Text
View/download PDF

2. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique – Actualisation 2021. Version courte

Author

Cottin, V., Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clément, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C.-H., Montani, D., Prévot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P.-Y., Campana, M., Chalabreysse, L., Chatté, G., Debieuvre, D., Ferretti, G., Fourrier, J.-M., Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J.-P., Mehdaoui, A., Naccache, J.-M., Paganon, C., Rémy-Jardin, M., Si-Mohamed, S., and Terrioux, P.

Published
2022
Full Text
View/download PDF

15. Deciphering a New Phenotype of Pulmonary Arterial Hypertension in Patients Carrying SOX17 Variants

Author

Montani, D., primary, Lechartier, B., additional, Girerd, B., additional, Eyries, M., additional, Ghigna, M.-R., additional, Savale, L., additional, Jais, X., additional, Seferian, A., additional, Jevnikar, M., additional, Boucly, A., additional, Riou, M., additional, Traclet, J., additional, Chaouat, A., additional, Levy, M., additional, Le Pavec, J., additional, Fadel, E., additional, Perros, F., additional, Soubrier, F., additional, Remy-Jardin, M., additional, Sitbon, O., additional, Bonnet, D., additional, and Humbert, M.J.C., additional

Published
2022
Full Text
View/download PDF

16. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

Author

Raghu, G. Remy-Jardin, M. Richeldi, L. Thomson, C.C. Antoniou, K.M. Bissell, B.D. Bouros, D. Buendia-Roldan, I. Caro, F. Crestani, B. Ewing, T. Ghazipura, M. Herman, D.D. Ho, L. Hon, S.M. Hossain, T. Inoue, Y. Johkoh, T. Jones, S. Kheir, F. Khor, Y.H. Knight, S.L. Kreuter, M. Lynch, D.A. Macrea, M. Maher, T.M. Mammen, M.J. Martinez, F.J. Molina-Molina, M. Morisset, J. Myers, J.L. Nicholson, A.G. Olson, A.L. Podolanczuk, A. Poletti, V. Ryerson, C.J. Selman, M. Strek, M.E. Troy, L.K. Wijsenbeek, M. Wilson, K.C. the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, Asociacion Latinoamericana de Torax

Subjects
respiratory system, respiratory tract diseases
Abstract

Background: This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociacion Latinoamericana de Torax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed of multidisciplinary experts in ILD, methodologists, and patient representatives. 1) Update of IPF: Radiological and histopathological criteria for IPF were updated by consensus. Questions about transbronchial lung cryobiopsy, genomic classifier testing, antacid medication, and antireflux surgery were informed by systematic reviews and answered with evidence-based recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. 2) Progressive pulmonary fibrosis (PPF): PPF was defined, and then radiological and physiological criteria for PPF were determined by consensus. Questions about pirfenidone and nintedanib were informed by systematic reviews and answered with evidence-based recommendations using the GRADE approach. Results: 1) Update of IPF: A conditional recommendation was made to regard transbronchial lung cryobiopsy as an acceptable alternative to surgical lung biopsy in centers with appropriate expertise. No recommendation was made for or against genomic classifier testing. Conditional recommendations were made against antacid medication and antireflux surgery for the treatment of IPF. 2) PPF: PPF was defined as at least two of three criteria (worsening symptoms, radiological progression, and physiological progression) occurring within the past year with no alternative explanation in a patient with an ILD other than IPF. A conditional recommendation was made for nintedanib, and additional research into pirfenidone was recommended. Conclusions: The conditional recommendations in this guideline are intended to provide the basis for rational, informed decisions by clinicians. © 2022 by the American Thoracic Society

Published
2022

17. French practical guidelines for the diagnosis and management of IPF-2021 update, short version

Author

Cottin, V, Bonniaud, P., Cadranel, J., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunes, H., Wemeau-Stervinou, L., Bergot, E., Blanchard, E., Borie, R., Bourdin, A., Chenivesse, C., Clement, A., Gomez, E., Gondouin, A., Hirschi, S., Lebargy, F., Marquette, C-H, Montani, D., Prevot, G., Quetant, S., Reynaud-Gaubert, M., Salaun, M., Sanchez, O., Trumbic, B., Berkani, K., Brillet, P-Y, Campana, M., Chalabreysse, L., Chatte, G., Debieuvre, D., Ferretti, G., Fourrier, J-M, Just, N., Kambouchner, M., Legrand, B., Le Guillou, F., Lhuillier, J-P, Mehdaoui, A., Naccache, J-M, Paganon, C., Remy-Jardin, M., Si-Mohamed, S., Terrioux, P., Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), RespiFIL, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Agro Dijon, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules (GRC 4 - Theranoscan), Sorbonne Université (SU), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Hôpital Avicenne [AP-HP], Université Sorbonne Paris Nord, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Coeur Poumon [CHU Lille], Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Hôpital Albert Calmette, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Trousseau [APHP], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Nouvel Hôpital Civil de Strasbourg, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de Recherche sur le Cancer et le Vieillissement (IRCAN), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), FHU OncoAge - Pathologies liées à l’âge [CHU Nice] (OncoAge), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Pharmacologie Moléculaire et Cellulaire [UNIV Côte d'Azur] (UPMC)-Université Côte d'Azur (UCA), Hôpital Pasteur [Nice] (CHU), Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Hôpital Bicêtre, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire [Grenoble] (CHU), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Hôpital Nord [CHU - APHM], Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Service de pneumologie, oncologie thoracique et soins intensifs respiratoires [Rouen], Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Informatique, du Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hypoxie et Poumon : pneumopathologies fibrosantes, modulations ventilatoires et circulatoires (H&P), UFR SMBH-Université Sorbonne Paris Nord, CHU Orléans, Groupement Hospitalier Lyon-Est (GHE), Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Université Grenoble Alpes (UGA), Centre Hospitalier Victor Provo, CHU Lille, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Etudes et de Recherche en Informatique Médicale [Lille] (CERIM), Centre Hospitalier Eure-Seine - Hôpital d'Evreux - Vernon (Evreux), Centre hospitalier Saint-Joseph [Paris], Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Biopsy, Interstitial lung disease, Common interstitial lung disease, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Pulmonary fibrosis
Abstract

National audience; Background. - Since the previous French guidelines were published in 2017, substantial additional knowledge about idiopathic pulmonary fibrosis has accumulated. Methods. - Under the auspices of the French-speaking Learned Society of Pulmonology and at the initiative of the coordinating reference center, practical guidelines for treatment of rare pulmonary diseases have been established. They were elaborated by groups of writers, reviewers and coordinators with the help of the OrphaLung network, as well as pulmonologists with varying practice modalities, radiologists, pathologists, a general practitioner, a head nurse, and a patients' association. The method was developed according to rules entitled "Good clinical practice" in the overall framework of the "Guidelines for clinical practice" of the official French health authority (HAS), taking into account the results of an online vote using a Likert scale. Results. - After analysis of the literature, 54 recommendations were formulated, improved, and validated by the working groups. The recommendations covered a wide-ranging aspects of the disease and its treatment: epidemiology, diagnostic modalities, quality criteria and interpretation of chest CT, indication and modalities of lung biopsy, etiologic workup, approach to familial disease entailing indications and modalities of genetic testing, evaluation of possible functional impairments and prognosis, indications for and use of antifibrotic therapy, lung transplantation, symptom management, comorbidities and complications, treatment of chronic respiratory failure, diagnosis and management of acute exacerbations of fibrosis. Conclusion. - These evidence-based guidelines are aimed at guiding the diagnosis and the management in clinical practice of idiopathic pulmonary fibrosis. (C) 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.

Published
2022
Full Text
View/download PDF

25. The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society

Author

Rubin, G.D., Ryerson, C.J., Haramati, L.B., Sverzellati, N., Kanne, J.P., Raoof, S., Schluger, N.W., Volpi, A., Yim, J.J., Martin, I.B.K., Anderson, D.J., Kong, C., Altes, T., Bush, A., Desai, S.R., Goldin, O., Goo, J.M., Humbert, M., Inoue, Y., Kauczor, H.U., Luo, F., Mazzone, P.J., Prokop, M., Remy-Jardin, M., Richeldi, L., Schaefer-Prokop, C.M., Tomiyama, N., Wells, A.U., Leung, A.N.C., Rubin, G.D., Ryerson, C.J., Haramati, L.B., Sverzellati, N., Kanne, J.P., Raoof, S., Schluger, N.W., Volpi, A., Yim, J.J., Martin, I.B.K., Anderson, D.J., Kong, C., Altes, T., Bush, A., Desai, S.R., Goldin, O., Goo, J.M., Humbert, M., Inoue, Y., Kauczor, H.U., Luo, F., Mazzone, P.J., Prokop, M., Remy-Jardin, M., Richeldi, L., Schaefer-Prokop, C.M., Tomiyama, N., Wells, A.U., and Leung, A.N.C.

Abstract

Contains fulltext : 220721.pdf (Publisher’s version ) (Closed access), With more than 900 000 confirmed cases worldwide and nearly 50 000 deaths during the first 3 months of 2020, the coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread of COVID-19 has been heterogeneous, resulting in some regions having sporadic transmission and relatively few hospitalized patients with COVID-19 and others having community transmission that has led to overwhelming numbers of severe cases. For these regions, health care delivery has been disrupted and compromised by critical resource constraints in diagnostic testing, hospital beds, ventilators, and health care workers who have fallen ill to the virus exacerbated by shortages of personal protective equipment. Although mild cases mimic common upper respiratory viral infections, respiratory dysfunction becomes the principal source of morbidity and mortality as the disease advances. Thoracic imaging with chest radiography and CT are key tools for pulmonary disease diagnosis and management, but their role in the management of COVID-19 has not been considered within the multivariable context of the severity of respiratory disease, pretest probability, risk factors for disease progression, and critical resource constraints. To address this deficit, a multidisciplinary panel comprised principally of radiologists and pulmonologists from 10 countries with experience managing patients with COVID-19 across a spectrum of health care environments evaluated the utility of imaging within three scenarios representing varying risk factors, community conditions, and resource constraints. Fourteen key questions, corresponding to 11 decision points within the three scenarios and three additional clinical situations, were rated by the panel based on the anticipated value of the information that thoracic imaging would be expected to provide. The results were aggregated, resulting in five main and three additional recommendations intended to guide medical practitioners i

Published
2020

26. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts

Author

Exter, P.L. den, Kroft, L.J., Gonsalves, C., Gal, G. Le, Schaefer-Prokop, C.M., Carrier, M., Huisman, M.V., Klok, F.A., Meijboom, L., Beenen, L.F., Roos, A, Hartmann, I., Dennie, C., Revel, M.P., Haramati, L., Beek, E. van, Screaton, N., Ferretti, G., Ghaye, B., Das, M., White, C., Fernandez, E. Pena, Paul, N., Vlahos, I., Renapurkar, R.D., Ravenel, J., Kanne, J., Abbara, S., Remy-Jardin, M., Geurts, B., Frauenfelder, T., Sverzellati, N., Prosch, H., Goo, J.M., Vogel-Claussen, J., MacMahon, P.J., Bhalla, S., Kahn, S., Shivakumar, S., Wells, P., Rodger, M., Castellucci, L., Duffett, L., Delluc, A., Siegal, D., Lazo-Langner, A., Wu, C., Lee, A, Garcia, D., Zwicker, J., Aujesky, D., Jimenez, D., Righini, M., Blondon, M., Ay, C., Barco, S., Kamphuisen, P.W., Ferreira, M., Sanchez, O., Moores, L.K., Tromeur, C., Ageno, W., Hunt, B., Prandoni, P., Monreal, M., Crowther, M., Roy, P.M., Pabinger, I., Donadini, M.P., Moustafa, F., Jara-Palomares, L., Pedroc, R., Bertoletti, L., Verhamme, P., Eikenboom, H., Meer, F. van der, Buller, H.R., Es, N. van, Exter, P.L. den, Kroft, L.J., Gonsalves, C., Gal, G. Le, Schaefer-Prokop, C.M., Carrier, M., Huisman, M.V., Klok, F.A., Meijboom, L., Beenen, L.F., Roos, A, Hartmann, I., Dennie, C., Revel, M.P., Haramati, L., Beek, E. van, Screaton, N., Ferretti, G., Ghaye, B., Das, M., White, C., Fernandez, E. Pena, Paul, N., Vlahos, I., Renapurkar, R.D., Ravenel, J., Kanne, J., Abbara, S., Remy-Jardin, M., Geurts, B., Frauenfelder, T., Sverzellati, N., Prosch, H., Goo, J.M., Vogel-Claussen, J., MacMahon, P.J., Bhalla, S., Kahn, S., Shivakumar, S., Wells, P., Rodger, M., Castellucci, L., Duffett, L., Delluc, A., Siegal, D., Lazo-Langner, A., Wu, C., Lee, A, Garcia, D., Zwicker, J., Aujesky, D., Jimenez, D., Righini, M., Blondon, M., Ay, C., Barco, S., Kamphuisen, P.W., Ferreira, M., Sanchez, O., Moores, L.K., Tromeur, C., Ageno, W., Hunt, B., Prandoni, P., Monreal, M., Crowther, M., Roy, P.M., Pabinger, I., Donadini, M.P., Moustafa, F., Jara-Palomares, L., Pedroc, R., Bertoletti, L., Verhamme, P., Eikenboom, H., Meer, F. van der, Buller, H.R., and Es, N. van

Abstract

Contains fulltext : 229597.pdf (publisher's version ) (Open Access), Background: Improved imaging techniques have increased the incidence of subsegmental pulmonary embolism (ssPE). Indirect evidence is suggesting that ssPE may represent a more benign presentation of venous thromboembolism not necessarily requiring anticoagulant treatment. However, correctly diagnosing ssPE is challenging with reported low interobserver agreement, partly due to the lack of widely accepted diagnostic criteria. Objectives: We sought to derive uniform diagnostic criteria for ssPE, guided by expert consensus. Methods: Based on an extensive literature review and expert opinion of a Delphi steering committee, two surveys including statements regarding diagnostic criteria and management options for ssPE were established. These surveys were conducted electronically among two panels, respectively: expert thoracic radiologists and clinical venous thromboembolism specialists. The Delphi method was used to achieve consensus after multiple survey rounds. Consensus was defined as a level of agreement >70%. Results: Twenty-nine of 40 invited radiologists (73%) and 40 of 51 clinicians (78%) participated. Following two survey rounds by the expert radiologists, consensus was achieved on 15 of 16 statements, including on the established diagnostic criteria for ssPE (96% agreement): a contrast defect in a subsegmental artery, that is, the first arterial branch division of any segmental artery independent of artery diameter, visible in at least two subsequent axial slices, using a computed tomography scanner with a desired maximum collimator width of

Published
2020

27. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society

Author

Hatabu, H., Hunninghake, G. M., Richeldi, Luca, Brown, K. K., Wells, A. U., Remy-Jardin, M., Verschakelen, J., Nicholson, A. G., Beasley, M. B., Christiani, D. C., San Jose Estepar, R., Seo, J. B., Johkoh, T., Sverzellati, N., Ryerson, C. J., Graham Barr, R., Goo, J. M., Austin, J. H. M., Powell, C. A., Lee, K. S., Inoue, Y., Lynch, D. A., Richeldi L. (ORCID:0000-0001-8594-1448), Hatabu, H., Hunninghake, G. M., Richeldi, Luca, Brown, K. K., Wells, A. U., Remy-Jardin, M., Verschakelen, J., Nicholson, A. G., Beasley, M. B., Christiani, D. C., San Jose Estepar, R., Seo, J. B., Johkoh, T., Sverzellati, N., Ryerson, C. J., Graham Barr, R., Goo, J. M., Austin, J. H. M., Powell, C. A., Lee, K. S., Inoue, Y., Lynch, D. A., and Richeldi L. (ORCID:0000-0001-8594-1448)

Abstract

The term interstitial lung abnormalities refers to specific CT findings that are potentially compatible with interstitial lung disease in patients without clinical suspicion of the disease. Interstitial lung abnormalities are increasingly recognised as a common feature on CT of the lung in older individuals, occurring in 4–9% of smokers and 2–7% of non-smokers. Identification of interstitial lung abnormalities will increase with implementation of lung cancer screening, along with increased use of CT for other diagnostic purposes. These abnormalities are associated with radiological progression, increased mortality, and the risk of complications from medical interventions, such as chemotherapy and surgery. Management requires distinguishing interstitial lung abnormalities that represent clinically significant interstitial lung disease from those that are subclinical. In particular, it is important to identify the subpleural fibrotic subtype, which is more likely to progress and to be associated with mortality. This multidisciplinary Position Paper by the Fleischner Society addresses important issues regarding interstitial lung abnormalities, including standardisation of the definition and terminology; predisposing risk factors; clinical outcomes; options for initial evaluation, monitoring, and management; the role of quantitative evaluation; and future research needs.

Published
2020

35. Reply to Moodley and to Ravaglia et al

Author

Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, Luca, and Wilson, K.

Subjects
Settore MED/09 - MEDICINA INTERNA, Humans, Idiopathic Pulmonary Fibrosis
Published
2019

46. Diagnosis of idiopathic pulmonary fibrosis An Official ATS/ERS/JRS/ALAT Clinical practice guideline

Author

Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, Luca, Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., Flaherty, K. R., Wells, A., Martinez, F. J., Azuma, A., Bice, T. J., Bouros, D., Brown, K. K., Collard, H. R., Duggal, A., Galvin, L., Inoue, Y., Gisli Jenkins, R., Johkoh, T., Kazerooni, E. A., Kitaichi, M., Knight, S. L., Mansour, G., Nicholson, A. G., Pipavath, S. N. J., Buendia-Roldan, I., Selman, M., Travis, W. D., Walsh, S., Wilson, K. C., Richeldi L. (ORCID:0000-0001-8594-1448), Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, Luca, Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., Flaherty, K. R., Wells, A., Martinez, F. J., Azuma, A., Bice, T. J., Bouros, D., Brown, K. K., Collard, H. R., Duggal, A., Galvin, L., Inoue, Y., Gisli Jenkins, R., Johkoh, T., Kazerooni, E. A., Kitaichi, M., Knight, S. L., Mansour, G., Nicholson, A. G., Pipavath, S. N. J., Buendia-Roldan, I., Selman, M., Travis, W. D., Walsh, S., Wilson, K. C., and Richeldi L. (ORCID:0000-0001-8594-1448)

Abstract

Background: This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Methods: The evidence syntheses were discussed and recommendations formulated by a multidisciplinary committee of IPF experts. The evidence was appraised and recommendations were formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation approach. Results: The guideline panel updated the diagnostic criteria for IPF Previously defined patterns of usual interstitial pneumonia (UIP) were refined to patterns of UIP, probable UIP, indeterminate, and alternate diagnosis. For patients with newly detected interstitial lung disease (ILD) who have a high-resolution computed tomography scan pattern of probable UIP, indeterminate, or an alternative diagnosis, conditional recommendations were made for performing BAL and surgical lung biopsy; because of lack of evidence, no recommendation was made for or against performing transbronchial lung biopsy or lung cryobiopsy. In contrast, for patients with newly detected ILD who have a high-resolution computed tomography scan pattern of UIP, strong recommendations were made against performing surgical lung biopsy, transbronchial lung biopsy, and lung cryobiopsy, and a conditional recommendation was made against performing BAL. Additional recommendations included a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs. Conclusions: The guideline panel provided recommendations related to the diagnosis of IPF.

Published
2018

49. THU0430 Description and prognosis factors of systemic sclerosis-associated interstitial lung disease outcome on serial hrct

Author

Forestier, A., primary, le gouellec, N., additional, duhamel, A., additional, kramer, G., additional, perez, T., additional, sobanski, V., additional, morell dubois, S., additional, lambert, M., additional, hatron, P.-Y., additional, hachulla, E., additional, behal, H., additional, matran, R., additional, launay, D., additional, and remy jardin, M., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results